Involvement of oncogenic tyrosine kinase NPM-ALK in trifluoperazine-induced cell cycle arrest and apoptosis in ALK⁺ anaplastic large cell lymphoma

References

• Amin HM, Lai R. Pathobiology of ALK+ anaplastic large-cell lymphoma. Blood. 2007;110:2259–2267. doi: 10.1182/blood-2007-04-060715
   PubMed Web of Science ®Google Scholar
• Greenland C, Touriol C, Chevillard G, et al. Expression of the oncogenic NPM-ALK chimeric protein in human lymphoid T-cells inhibits drug-induced, but not Fas-induced apoptosis. Oncogene. 2001;20:7386–7397. doi: 10.1038/sj.onc.1204870
   PubMed Web of Science ®Google Scholar
• Shi P, Lai R, Lin Q, et al. IGF-IR tyrosine kinase interacts with NPM-ALK oncogene to induce survival of T-cell ALK + anaplastic large-cell lymphoma cells. Blood. 2009;114:360–370. doi: 10.1182/blood-2007-11-125658
   PubMed Web of Science ®Google Scholar
• Brugieres L, Deley MC, Pacquenment H, et al. CD30+ anaplastic large-cell lymphoma in children: analysis of 82 patients enrolled in two consecutive studies of the French society of pediatric oncology. Blood. 1998;92:3591–3598.
   PubMed Web of Science ®Google Scholar
• Brugières L, Quartier P, Le Deley MC, et al. Relapses of childhood anaplastic large-cell lymphoma: treatment results in a series of 41 children – a report from the French society of pediatric oncology. Ann Oncol. 2000;11:53–58. doi: 10.1023/A:1008352726155
   PubMed Web of Science ®Google Scholar
• Laver JH, Kraveka JM, Hutchison RE, et al. Advanced-stage large-cell lymphoma in children and adolescents: results of a randomized trial incorporating intermediate-dose methotrexate and high-dose cytarabine in the maintenance phase of the APO regimen: a pediatric oncology group phase Ш trial. J Clin Oncol. 2005;23:541–547. doi: 10.1200/JCO.2005.11.075
   PubMed Web of Science ®Google Scholar
• Ceccon M, Mologni L, Giudici G, et al. Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma. Mol Cancer Res. 2015;13:775–783. doi: 10.1158/1541-7786.MCR-14-0157
   PubMed Web of Science ®Google Scholar
• Ceccon M, Mologni L, Bisson W, et al. Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors. Mol Cancer Res. 2013;11:122–132. doi: 10.1158/1541-7786.MCR-12-0569
   PubMed Web of Science ®Google Scholar
• Shin SY, Kim SY, Kim JH, et al. Induction of early growth response-1 gene expression by calmodulin antagonist trifluoperazine through the activation of Elk-1 in human fibrosarcoma HT1080 cells. J Biol Chem. 2001;276:7797–7805. doi: 10.1074/jbc.M009465200
   PubMed Web of Science ®Google Scholar
• Feldkamp MD, Gakhar L, Pandey N, et al. Opposing orientations of the anti-psychotic drug trifluoperazine selected by alternate conformations of M144 in calmodulin. Proteins. 2015;83:989–996. doi: 10.1002/prot.24781
   PubMed Web of Science ®Google Scholar
• Kang S, Hong J, Lee JM, et al. Trifluoperazine, a well-known antipsychotic, inhibits glioblastoma invasion by binding to calmodulin and disinhibiting calcium release channel IP3R. Mol Cancer Ther. 2017;16:217–227. doi: 10.1158/1535-7163.MCT-16-0169-T
   PubMed Web of Science ®Google Scholar
• Shin SY, Choi BH, Kim JR, et al. Suppression of P-glycoprotein expression by antipsychotics trifluoperazine in Adriamycin-resistant L1210 mouse leukemia cells. Eur J Pharm Sci. 2006;28:300–306. doi: 10.1016/j.ejps.2006.03.002
   PubMed Web of Science ®Google Scholar
• Gangopadhyay S, Karmakar P, Dasgupta U, et al. Trifluoperazine stimulates ionizing radiation induced cell killing through inhibition of DNA repair. Mutat Res. 2007;633:117–125. doi: 10.1016/j.mrgentox.2007.05.011
   PubMed Web of Science ®Google Scholar
• Gross A. Bcl-2 proteins: regulators of the mitochondrial apoptotic program. IUBMB Life. 2001;52:231–236. doi: 10.1080/15216540152846046
   PubMed Web of Science ®Google Scholar
• Zhelev Z, Ohba H, Bakalova R, et al. Phenothiazines suppress proliferation and induce apoptosis in cultured leukemic cells without any influence on the viability of normal lymphocytes. Cancer Chemoth Pharm. 2004;53:267–275. doi: 10.1007/s00280-003-0738-1
   PubMed Web of Science ®Google Scholar
• Chen Q, Wu LJ, Wu YQ, et al. Molecular mechanism of trifluoperazine induces apoptosis in human A549 lung adenocarcinoma cell lines. Mol Med Rep. 2009;2:811–817.
   PubMed Web of Science ®Google Scholar
• Hait HN, Grais L, Benz C, et al. Inhibition of growth of leukemic cells by inhibitors of calmodulin: phenothiazines and melittin, cancer. Chemoth Pharm. 1985;14:202–205.
   PubMed Web of Science ®Google Scholar
• Ganapathi R, Yen A, Grabowski D, et al. Role of the calmodulin inhibitor trifluoperazine on the induction and expression of cell cycle traverse perturbations and cytotoxicity of daunorubicin and doxorubicin (Adriamycin) in doxorubicin-resistant P388 mouse leukaemia cells. Br J Cancer. 1986;53:561–566. doi: 10.1038/bjc.1986.88
   PubMed Web of Science ®Google Scholar
• Wang Z, Nishikawa Y, Wang M, et al. Induction of apoptosis via mitogen-activated protein kinase pathway by a K vitamin analog in rat hepatocytes. J Hepatol. 2002;36:85–92. doi: 10.1016/S0168-8278(01)00230-6
   PubMed Web of Science ®Google Scholar
• Xu HY Y, Guan XL, et al. Expression of regulating apoptosis gene and apoptosis index in primary liver cancer. World J Gastroenterol. 2000;6:721–724. doi: 10.3748/wjg.v6.i5.721
   PubMed Web of Science ®Google Scholar
• Staber PB, Vesely P, Haq N, et al. The oncoprotein NPM-ALK of anaplastic large cell lymphoma induces JUNB transcription via ERK1/2 and JunB translation via mTOR signaling. Blood. 2007;110:3374–3383. doi: 10.1182/blood-2007-02-071258
   PubMed Web of Science ®Google Scholar
• Hamedani FS, Cinar M, Mo Z, et al. Crizotinib (PF-2341066) induces apoptosis due to downregulation of pSTAT3 and BCL-2 family proteins in NPM-ALK+ anaplastic large cell lymphoma. Leukmia Res. 2014;38:503–508. doi: 10.1016/j.leukres.2013.12.027
   PubMed Web of Science ®Google Scholar
• Mochizuki T, Furuta S, Mitsushita J, et al. Inhibition of NADPH oxidase 4 activates apoptosis via the AKT/apoptosis signal-regulating kinase 1 pathway in pancreatic cancer PANC-1 cells. Oncogene. 2006;25:3699–3707. doi: 10.1038/sj.onc.1209406
   PubMed Web of Science ®Google Scholar
• Ruchatz H, Coluccia AML, Stano P, et al. Constitutive activation of Jak2 contributes to proliferation and resistance to apoptosis in NPM/ALK-transformed cells. Ex Hematol. 2003;31:309–315. doi: 10.1016/S0301-472X(03)00007-9
   PubMed Web of Science ®Google Scholar
• Zamo A, Chiarle R, Piva R, et al. Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Oncogene. 2002;21:1038–1047. doi: 10.1038/sj.onc.1205152
   PubMed Web of Science ®Google Scholar
• Humbert L, Ghozlan M, Canaff L, et al. The leukemia inhibitory factor (LIF) and p21 mediate the TGFβ tumor suppressive effects in human cutaneous melanoma. BMC Cancer. 2015;15:3635–3616. doi: 10.1186/s12885-015-1177-1
   Web of Science ®Google Scholar
• Zhao D, Besser AH, Wander SA, et al. Cytoplasmic p27 promotes epithelial–mesenchymal transition and tumor metastasis via STAT3-mediated Twist1 upregulation. Oncogene. 2015;34:5447–5459. doi: 10.1038/onc.2014.473
   PubMed Web of Science ®Google Scholar
• Zhao J, Lin W, Cao Z, et al. Total alkaloids of Rubus aleaefolius poir. inhibit the STAT3 signaling pathway leading to suppression of proliferation and cell cycle arrest in a mouse model of hepatocellular carcinoma. Oncol Rep. 2013;30:1309–1314. doi: 10.3892/or.2013.2585
   PubMed Web of Science ®Google Scholar